Castle Biosciences Inc CSTL
News
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
Castle Biosciences to Open New Laboratory Facility in Scottsdale
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
JAAD Publication Shows Improved Performance of DecisionDx®-SCC
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
Castle Biosciences Reports Second Quarter 2026 Results
